Guidelines for authors and peer reviewers of economic submissions to the BMJ

British Medical Journal

Volumn 313, Issue 7052, 1996, Pages 275-283

  Drummond, M F ^a   Jefferson, T O ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b MINISTRY OF DEFENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; HEALTH ECONOMICS; INFORMATION PROCESSING; MEDICAL LITERATURE; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; WRITING;

EID: 0030056579     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.313.7052.275     Document Type: Review

References (48)

1. Elixhauser A, ed. Health care cost benefit and cost-effectiveness analysis (cost benefit analysis/cost effectiveness analysis). From 1979 to 1990:a bibliography. Medical Care 1993;31(suppl):JS1-149.
2. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy 1992;21:249-79.
3. Udvarhelyi S, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are methods being used correctly? Ann Intern Med 1992;116:238-44.
4. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomised controlled trials. Medical Care 1992;30:231-8.
5. Jefferson TO, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Economics 1994;3:25-37.
6. Williams AH. The cost-benefit approach. Br Med Bull 1974;30:252-6.
7. Drummond MF, Brandt A, Luce B, Rovira J. Standardising methodologies for economic evaluation in health care. International Journal of Technology Assessment in Health Care 1993;9:26-36.
8. Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Australian Government Publishing Service, 1992.
9. Ministry of Health (Ontario). Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ministry of Health, 1994.
10. Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconomics 1995;8:169-74.
11. Department of Health and Association of British Pharmaceutical Industry. Guidelines for the economic evaluation of pharmaceutical [press release]. London: Department of Health, 1994.
12. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.
13. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles, Ann Intern Med 1995;123:61-70
14. NHS Centre for Reviews and Dissemination. The NHS economic evaluation database. York: CRD, 1996.
15. Kassirer JP, Angel M. The journal's policy on cost effectiveness analyses. N Engl J Med 1994;331:669-70.
16. Schulman K, Sulmasy DP, Roney D. Ethics, economics and the publication policies of major medical journals. JAMA 1994;272:154-6.
17. Jefferson TO, Demicheli V. Are guidelines for peer reviewing economic evaluations necessary? A survey of current editorial practice, Health Economics 1995;4:383-8.
18. Smith R. Conflict of interest and the BMJ. BMJ 1994;308:4-5.
19. Drummond, MF, Stoddart GL, Torrance GW Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
20. Jefferson TO, Demicheli V, Entwistle V. Assessing quality of economic submissions to the BMJ. BMJ 1995;311:393-4.
21. Guidelines for referees. BMJ 1996;312:41-4.
22. Mehrez A, Gafni A. Quality-adjusted life-years, utility theory and healthy years equivalents. Medical Decision Making 1989;9:142-9
23. Mugford M, Kingston J, Chalmers I. Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources. BMJ 1989;299:1003-6.
24. Sacken DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology:a basic science for clinical medicine. 2nd ed. Boston: Little Brown, 1991.
25. Kind P. The EuroQoL Instrument: an index of health-related quality of life. In Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials.2nd ed. Philadelphia: Lippincott-Raven, 1996: 191-202.
26. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: health utilities index. PharmacoEconomics 1995;7:490-502.
27. Avorn J. Benefit and cost analysis in geriatric care: turning age discrimination into health policy. N Engl J Med 1994;310:1294-1300.
28. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. Journal of Health Economics 1995;14:171-89.
29. Wald N. Couple screening for cystic fibrosis. Lancet 1991;338:1318.
30. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Jones RP, et al. Issues in the cross-national assessment of health technology. International Journal of Technology Assessment in Health Care 1992;8:671-82.
31. Organisation for Economic Cooperation and Development. Purchasing power parities. Paris: OECD, 1993.
32. World Bank. World development report 1993. New York: Oxford University Press, 1993.
33. Schulman KA, Lynne LA, Glick HN, Eisenberg JM. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human-immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-801.
34. Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease: the case of cholestyramine, JAMA 1987;258:2381-7.
35. Fordham R, Field DJ, Hodges S, Normand C, Mason E, Burton P, et al. Cost of neonatal care across a health authority. J Pub Health Med 1992;61:127-30.
36. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA 1994;272:773-80.
37. Egberts J. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks gestation. Biology of the Neonate 1992;61:59-85.
38. Schulman KA, Yabroff R, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Information Journal 1995;29:1405-14.
39. Parsonage M, Neuburger H. Discounting and health benefits. Health Economics 1992;1:71-6.
40. Cairns J. Discounting and health benefits: another perspective. Health Economics 1992;1:76-9.
41. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Economics 1995;4(5):355-72.
42. Briggs AH, Sculpher MJ, Buxton MJ. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics 1994;3:95-104.
43. O'Brien B, Drummond MF, Labelle R, Willan A. In search of power and significance: issues in the design and analysis of stochastic economic appraisals. Medical Care 1994;32:150-63.
44. van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and cost effectiveness ratios alongside a clinical trial. Health Economics 1995;3(5):309-19.
45. Wakker P, Klaassen MF. Confidence intervals for cost effectiveness ratios. Health Economics 1995;4(5):373-81.
46. Drummond, MF, Mason J, Torrance G. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993;37:33-40.
47. Birch S, Gafni A. Cost-effectiveness ratios: in a league of their own. Health Policy 1994;28:133-41.
48. Johannesson M. The relationship between cost effectiveness analysis and cost benefit analysis. Soc Sci Med 1995;41:483-9.